-+ 0.00%
-+ 0.00%
-+ 0.00%

Tiziana presents Phase 2a intranasal foralumab MSA trial poster at World Parkinson Congress

PUBT·04/14/2026 11:01:34
Listen to the news
Tiziana presents Phase 2a intranasal foralumab MSA trial poster at World Parkinson Congress
  • Tiziana Life Sciences flagged a late-breaking poster on its Phase 2a trial of intranasal foralumab in Multiple System Atrophy (MSA), scheduled for presentation at 7th World Parkinson Congress on May 24-27, 2026.
  • Poster will outline trial design and rationale, not clinical results.
  • Study tests whether intranasal foralumab can reduce neuroinflammation tied to disease progression in MSA, condition with no approved disease-modifying therapy.
  • Open-label Phase 2a trial plans to enroll up to 10 patients for 6 months of dosing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604140700OMX_____CNEWS_EN_GNW9689299_en) on April 14, 2026, and is solely responsible for the information contained therein.